Days af­ter FDA clears C3 drug, Apel­lis spot­lights ex-US PhI­II win among pa­tients who haven't tak­en Soliris

Through­out Apel­lis’ de­vel­op­ment pro­gram for pegc­eta­coplan — es­pe­cial­ly lead­ing up to its ap­proval days ago — CEO Cedric Fran­cois has of­ten billed its C3 in­hibitor as a chal­lenger to Alex­ion’s block­buster C5 drug Soliris, and it sug­gest­ed as much in the piv­otal study lead­ing to the FDA’s green light.

But out­side the US, there are mar­kets where pa­tients may not have ready ac­cess to Soliris. And Apel­lis says it now has the da­ta sug­gest­ing the drug, now brand­ed Em­paveli, is just as com­pet­i­tive in the treat­ment-naïve pop­u­la­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER